LivaNova PLC (LIVN) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $74.80, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.3% away).
LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion, cannulae) and Neuromodulation (VNS Therapy for epilepsy and depression, plus OSA pipeline). Products are sold through direct sales and... Read more
Hold if already holding. Not a fresh buy at $74.80, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.3% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — LivaNova PLC
Latest news
- NEWS LivaNova (LIVN) Projected to Post Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS LivaNova PLC (LIVN) Shares Fall 3.3% -- GF Value Says Still Over - GuruFocus — GuruFocus neutral
- NEWS Earnings call transcript: LivaNova PLC beats Q1 2026 estimates, shares rise - Investing.com Canada — Investing.com Canada positive
- NEWS LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Earnings Flash (LIVN) LivaNova PLC Reports Q1 Revenue $362.3M, vs. FactSet Est of $346.1M - marketscreener.com — marketscreener.com positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $74.80, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (1.3% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $74.29 (-0.7%), stop $69.68 (−7.3%), A.R:R -0.8:1. Score 5.9/10, moderate confidence.
Take-profit target: $74.29 (-0.7% upside). Target $74.29 (-0.7%), stop $69.68 (−7.3%), A.R:R -0.8:1. Stop-loss: $69.68.
Analyst target reached - limited upside remaining; Near 52-week high (1.3% away).
LivaNova PLC trades at a P/E of 36.9 (forward 15.6). TrendMatrix value score: 6.0/10. Verdict: Hold.
16 analysts cover LIVN with a consensus score of 4.2/5. Average price target: $81.
What does LivaNova PLC do?LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators,...
LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion, cannulae) and Neuromodulation (VNS Therapy for epilepsy and depression, plus OSA pipeline). Products are sold through direct sales and distributors in 100+ countries; the U.S. contributed 53%, Europe 19%, and Rest of World 28% of 2025 net revenue.